Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 4, 2005. The report details a share repurchase transaction, updates on directors' interests, the publication of the 2004 Annual Report, and a significant regulatory disruption regarding the supply of two pharmaceutical products.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. It references the publication of the 2004 Annual Report for full financial data.
- Share Repurchase: 200,000 ordinary shares purchased on March 3, 2005, at 13.0863 pence per share.
- Treasury Shares: Total holdings increased to 76,848,000 shares.
- Shares in Issue: 5,862,997,296 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the FDA-mandated halt in distribution for two key medicines due to manufacturing issues:
- Avandamet: Used to treat type 2 diabetes (all strengths: 1 mg, 2 mg, 4 mg).
- Paxil CR: Used to treat depression and anxiety disorders (all strengths: 12.5 mg, 25 mg, 37.5 mg).
- Impact: Short-term shortage of patient supplies is expected.
Additionally, the GSK Trust transferred 192,838 ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
Management Commentary: GSK states that the manufacturing issues do not pose a health risk to patients. The company advises patients to continue taking their medication and consult healthcare providers with questions. GSK is working with the FDA to resolve the issues as quickly as possible.
Risks and Contingencies: The immediate risk is a supply shortage for Avandamet and Paxil CR. The filing notes that the 2004 Annual Report and Annual Review were published on the company website on March 4, 2005, with hard copies to be distributed around March 24, 2005.
Investor Verification Checklist
- Verify the duration and resolution timeline of the FDA supply halt for Avandamet and Paxil CR.
- Review the full 2004 Annual Report for comprehensive financial performance data not included in this filing.
- Monitor subsequent filings for updates on the manufacturing issues and potential financial impact of the supply shortage.
- Confirm the status of the 2004 Annual General Meeting notice and shareholder communications.